Woodley Farra Manion Portfolio Management Inc. acquires 4,434 shares of Johnson & Johnson (NYSE: JNJ)

0

Woodley Farra Manion Portfolio Management Inc. increased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) shares by 2.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund held 220,017 shares of the company after acquiring an additional 4,434 shares during the period. Johnson & Johnson accounts for 2.9% of Woodley Farra Manion Portfolio Management Inc.’s holdings, making the stock its 20th-largest position. Woodley Farra Manion Portfolio Management Inc.’s holdings in Johnson & Johnson were worth $38,994,000 at the end of last quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Family CFO Inc bought a new position in Johnson & Johnson stock in the fourth quarter worth $26,000. Steward Financial Group LLC bought a new position in Johnson & Johnson stock in the fourth quarter worth $34,000. Joseph P. Lucia & Associates LLC bought a new position in Johnson & Johnson stock in the first quarter worth $38,000. Advocacy Wealth Management Services LLC increased its holdings of Johnson & Johnson stock by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company worth $41,000 after buying 67 additional shares last quarter. Finally, Gibson Wealth Advisors LLC bought a new position in Johnson & Johnson stock in the fourth quarter worth $49,000. Hedge funds and other institutional investors own 68.78% of the company’s shares.

Johnson & Johnson shares down 0.4%

JNJ stock opened at $171.11 on Friday. The company has a market capitalization of $449.88 billion, a PE ratio of 24.91, a P/E/G ratio of 3.27 and a beta of 0.59. The company has a debt ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The company’s fifty-day moving average is $175.21 and its 200-day moving average is $174.60. Johnson & Johnson has a one-year low of $155.72 and a one-year high of $186.69.

Johnson & Johnson Inc (NYSE:JNJ – Get Rating) last released its quarterly results on Tuesday, July 19. The company reported EPS of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. The company posted revenue of $24.02 billion for the quarter, versus analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s revenue increased 3.0% year over year. In the same quarter last year, the company earned earnings per share of $2.48. On average, research analysts expect Johnson & Johnson to post EPS of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. The ex-dividend date is Monday, August 22. This represents an annualized dividend of $4.52 and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Insider activity

In other news, CAO Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade dated Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accountant now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, accessible via the SEC’s website. In other news, CAO Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade dated Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accountant now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, accessible via the SEC’s website. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction dated Friday, June 10. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The disclosure of this sale can be found here. Insiders of the company own 0.35% of the shares of the company.

Analysts set new price targets

A number of research companies have published reports on JNJ. Wells Fargo & Company raised its price target on Johnson & Johnson stock from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 report. Daiwa Capital Markets assumed coverage for Johnson & Johnson shares in a Wednesday, June 22 research note. They issued an “outperformance” rating on the stock. Credit Suisse Group raised its price target on Johnson & Johnson shares from $200.00 to $205.00 and gave the stock an “outperform” rating in a Wednesday, April 20 research note. Morgan Stanley raised its price target on Johnson & Johnson shares from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 research note. Finally, Goldman Sachs Group raised its price target on Johnson & Johnson shares from $163.00 to $181.00 and gave the stock a “neutral” rating in a Tuesday, April 12 research note. . Four investment analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company a strong buy rating. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Company Profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

See also

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

About Author

Comments are closed.